Table 3.
Medical applications of OGP and OGP(10–14) peptides.
| Peptide | Application | Model | Defects | Reference |
|---|---|---|---|---|
| OGP | Intravenous administration | Male rats | Increased trabecular bone mass in the mandibular condyles | [33] |
| OGP | Intravenous administration | Male rabbits | The callus formation and cortical healing is enhanced by OGP treatment in tibiae fracture | [39] |
| OGP | Intravenous administration | Ovariectomized female mice | Reverses the trabecular bone loss in ovariectomized mice | [40] |
| OGP | Subcutaneous administration | Male rats | Promotes an earlier bone-repair callus in femoral fracture | [38] |
| OGP | Intravenous administration | Male rats | Improved callus formation and function in femoral fracture | [63] |
| OGP | Poly (lactic-co-glycolic) acid scaffolds | Male rabbits | Accelerates healing of segmental radius bone defects | [66] |
| OGP | Intravenous administration | Male rabbits | Promotes optimal new bone formation during distraction osteogenesis | [64] |
| OGP | Calcium phosphate thin films | Not Applied | Not Applied | [59] |
| OGP and OGP(10–14) | Bacterial Cellulose Membrane | CHO-K1 and osteoblastic cells | No cytotoxic, genotoxic or mutagenic effects of BC membranes | [68] |
| OGP(10–14) | Poly(ester urea) homopolymers | hMSCs and Male rats | Significant tissue-scaffold integration and promotion of osteogenesis/angiogenesis | [45] |
| OGP | Mesoporous silica and mesoporous silica/apatite | Not Applied | Not Applied | [70] |
| OGP(10–14) | Alginate hydrogels | Immunodeficient male mice | OGP increases the hydrogels degradation and the vascularized connective tissue colonization evaluated by subcutaneous implantation | [71] |
| OGP and OGP(10–14) | Bacterial cellulose-hydroxiapatite membrane | Male mice | Enhances bone formation in critical-size calvarial defects in mice mainly in early stages of bone regeneration | [69] |